Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hysterectomy | 7 | 2020 | 52 | 1.760 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2019 | 47 | 1.320 |
Why?
|
| Menorrhagia | 3 | 2017 | 4 | 1.160 |
Why?
|
| Leiomyoma | 3 | 2018 | 15 | 1.160 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 29 | 1.110 |
Why?
|
| Preoperative Care | 3 | 2019 | 125 | 1.110 |
Why?
|
| Laparoscopy | 7 | 2018 | 184 | 1.020 |
Why?
|
| Endometriosis | 2 | 2017 | 24 | 0.930 |
Why?
|
| Endometrial Ablation Techniques | 3 | 2017 | 5 | 0.760 |
Why?
|
| Gynecology | 2 | 2019 | 18 | 0.670 |
Why?
|
| Uterine Neoplasms | 2 | 2018 | 26 | 0.660 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 28 | 0.630 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 18 | 0.550 |
Why?
|
| Postoperative Complications | 3 | 2020 | 823 | 0.550 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 68 | 0.550 |
Why?
|
| Critical Pathways | 1 | 2018 | 47 | 0.550 |
Why?
|
| Perioperative Care | 1 | 2018 | 51 | 0.540 |
Why?
|
| Female | 23 | 2020 | 19945 | 0.540 |
Why?
|
| Cecal Diseases | 1 | 2017 | 2 | 0.530 |
Why?
|
| Appendix | 1 | 2017 | 6 | 0.530 |
Why?
|
| Hysteroscopy | 1 | 2017 | 4 | 0.530 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 199 | 0.500 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 252 | 0.490 |
Why?
|
| Models, Theoretical | 1 | 2017 | 139 | 0.490 |
Why?
|
| Endometrium | 1 | 2016 | 44 | 0.490 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 130 | 0.480 |
Why?
|
| Anticoagulants | 1 | 2016 | 122 | 0.450 |
Why?
|
| Humans | 25 | 2020 | 32282 | 0.440 |
Why?
|
| Abdominal Wall | 1 | 2014 | 24 | 0.430 |
Why?
|
| Uterus | 3 | 2020 | 77 | 0.430 |
Why?
|
| Adult | 14 | 2020 | 9259 | 0.410 |
Why?
|
| Uterine Cervical Diseases | 1 | 2013 | 2 | 0.400 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 51 | 0.390 |
Why?
|
| Surgical Mesh | 1 | 2013 | 50 | 0.380 |
Why?
|
| Middle Aged | 10 | 2020 | 11851 | 0.280 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2018 | 5 | 0.280 |
Why?
|
| Levonorgestrel | 2 | 2017 | 3 | 0.270 |
Why?
|
| Databases, Factual | 2 | 2020 | 368 | 0.270 |
Why?
|
| Obesity | 3 | 2020 | 1111 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3416 | 0.240 |
Why?
|
| United States | 4 | 2020 | 4072 | 0.220 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2004 | 17 | 0.210 |
Why?
|
| Water | 1 | 2004 | 65 | 0.200 |
Why?
|
| RNA | 1 | 2004 | 94 | 0.200 |
Why?
|
| Organ Size | 2 | 2020 | 221 | 0.190 |
Why?
|
| DNA | 1 | 2004 | 223 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2020 | 1840 | 0.170 |
Why?
|
| Risk Factors | 3 | 2018 | 3934 | 0.170 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 4 | 0.160 |
Why?
|
| Fertilization | 1 | 2020 | 5 | 0.160 |
Why?
|
| Patient Admission | 1 | 2019 | 54 | 0.150 |
Why?
|
| Teaching | 1 | 2019 | 60 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 98 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 95 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2019 | 79 | 0.140 |
Why?
|
| Incidence | 2 | 2020 | 1241 | 0.140 |
Why?
|
| Dyspareunia | 2 | 2017 | 6 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 242 | 0.140 |
Why?
|
| Adolescent | 4 | 2020 | 3519 | 0.130 |
Why?
|
| Young Adult | 3 | 2020 | 2649 | 0.130 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2017 | 5 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 14 | 0.130 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.130 |
Why?
|
| Intraoperative Period | 1 | 2017 | 43 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 33 | 0.130 |
Why?
|
| Appendectomy | 1 | 2017 | 19 | 0.130 |
Why?
|
| Vagina | 1 | 2017 | 61 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2017 | 54 | 0.130 |
Why?
|
| Internship and Residency | 2 | 2019 | 319 | 0.130 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2017 | 48 | 0.130 |
Why?
|
| Learning | 1 | 2017 | 84 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2016 | 19 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2017 | 251 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2017 | 137 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 47 | 0.120 |
Why?
|
| Peritoneal Cavity | 1 | 2016 | 5 | 0.120 |
Why?
|
| Abdominal Cavity | 1 | 2016 | 6 | 0.120 |
Why?
|
| Curriculum | 1 | 2017 | 203 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3626 | 0.110 |
Why?
|
| Hysterotomy | 1 | 2014 | 2 | 0.110 |
Why?
|
| Pregnancy, Ectopic | 1 | 2014 | 7 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 272 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2018 | 863 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 955 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 565 | 0.110 |
Why?
|
| Cicatrix | 1 | 2014 | 39 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2017 | 330 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 853 | 0.110 |
Why?
|
| Cathartics | 1 | 2014 | 5 | 0.100 |
Why?
|
| Enema | 1 | 2014 | 6 | 0.100 |
Why?
|
| Phosphates | 1 | 2014 | 26 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 65 | 0.100 |
Why?
|
| Vaginal Discharge | 1 | 2013 | 3 | 0.100 |
Why?
|
| North Carolina | 1 | 2017 | 1300 | 0.100 |
Why?
|
| Sacrum | 1 | 2013 | 18 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 395 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2013 | 26 | 0.100 |
Why?
|
| Overweight | 1 | 2015 | 252 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 2205 | 0.100 |
Why?
|
| Cues | 1 | 2012 | 65 | 0.090 |
Why?
|
| Quality of Life | 2 | 2017 | 964 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 443 | 0.090 |
Why?
|
| Nephrotic Syndrome | 2 | 2008 | 11 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2016 | 1425 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 907 | 0.080 |
Why?
|
| Cocaine | 1 | 2012 | 354 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 2316 | 0.070 |
Why?
|
| Levamisole | 1 | 2008 | 1 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 61 | 0.070 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 36 | 0.060 |
Why?
|
| Brain | 1 | 2012 | 965 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 553 | 0.060 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2004 | 5 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 23 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2004 | 57 | 0.050 |
Why?
|
| Temperature | 1 | 2004 | 58 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 48 | 0.050 |
Why?
|
| Base Sequence | 1 | 2004 | 252 | 0.050 |
Why?
|
| Remission Induction | 2 | 2015 | 92 | 0.040 |
Why?
|
| Research Design | 1 | 2004 | 314 | 0.040 |
Why?
|
| Pregnancy | 2 | 2015 | 961 | 0.040 |
Why?
|
| Contraception | 1 | 2020 | 11 | 0.040 |
Why?
|
| Abortion, Induced | 1 | 2020 | 7 | 0.040 |
Why?
|
| Temperament | 1 | 2019 | 1 | 0.040 |
Why?
|
| Attitude to Computers | 1 | 2019 | 16 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 112 | 0.040 |
Why?
|
| Mentors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Career Choice | 1 | 2019 | 43 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 45 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 230 | 0.040 |
Why?
|
| Ligaments | 1 | 2017 | 12 | 0.030 |
Why?
|
| Sexuality | 1 | 2017 | 14 | 0.030 |
Why?
|
| Students, Medical | 1 | 2019 | 126 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 50 | 0.030 |
Why?
|
| Decision Trees | 1 | 2017 | 30 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 456 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 883 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 191 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 122 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2008 | 146 | 0.030 |
Why?
|
| Cytological Techniques | 1 | 2016 | 17 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 23 | 0.030 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2015 | 3 | 0.030 |
Why?
|
| Dactinomycin | 1 | 2015 | 13 | 0.030 |
Why?
|
| Vincristine | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 37 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 38 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 70 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 461 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2014 | 114 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 252 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 10263 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2012 | 28 | 0.020 |
Why?
|
| Wakefulness | 1 | 2012 | 25 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 183 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 135 | 0.020 |
Why?
|
| Reward | 1 | 2012 | 64 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 231 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2012 | 122 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2012 | 190 | 0.020 |
Why?
|
| Child | 2 | 2008 | 2435 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1534 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 897 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1895 | 0.020 |
Why?
|
| Male | 3 | 2012 | 19441 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2008 | 73 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1224 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2007 | 42 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 292 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 101 | 0.020 |
Why?
|
| Age of Onset | 1 | 2007 | 90 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 252 | 0.010 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 338 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 655 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 757 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 854 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 1233 | 0.010 |
Why?
|
| European Continental Ancestry Group | 1 | 2007 | 1076 | 0.010 |
Why?
|
| Hispanic Americans | 1 | 2007 | 772 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2240 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 8199 | 0.010 |
Why?
|